Kidney disease
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Anika Sharma
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
Anika Sharma
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
Novartisā iptacopan impresses in phase 3 trial for rare kidney disease
Anika Sharma
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
Filspari fails to confirm kidney benefit in IgAN, but Travere hopes to keep FDA approval
Anika Sharma
Half a year after securing accelerated approval for the treatment of a rare kidney ailment, Travere Therapeuticsā groundbreaking drug, Filspari, ...
Addressing Low Diagnosis Rates for Kidney Disease: The Urgent Need for Better Screening, as Highlighted by AstraZeneca
SG Tylor
How AstraZenecaās Research Shows the Need for Improved Screening Methods to Tackle Low Diagnosis Rates for Kidney Disease AstraZeneca, the ...
